Steroid minimization for sirolimus-treated renal transplant recipients

Clinical Transplantation

Volumn 25, Issue 3, 2011, Pages 457-467

  Matas, Arthur J ^a   Granger, Darla ^b   Kaufman, Dixon B ^c   Sarwal, Minnie M ^d   Ferguson, Ronald M ^e   Woodle, E Steve ^f   Gill, John S ^g  

^a UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^b ST JOHN HOSPITAL AND MEDICAL CENTER   (United States)

^c NORTHWESTERN UNIVERSITY   (United States)

^d STANFORD UNIVERSITY SCHOOL OF MEDICINE   (United States)

^e THE OHIO STATE UNIVERSITY COLLEGE OF MEDICINE   (United States)

^f UNIVERSITY OF CINCINNATI   (United States)

^g ST PAUL S HOSPITAL   (Canada)

Author keywords

Immunosuppression; Kidney transplantation; Sirolimus; Steroid minimization

Indexed keywords

ALEMTUZUMAB; BASILIXIMAB; CALCINEURIN INHIBITOR; CORTICOSTEROID; CREATININE; CYCLOSPORIN A; DACLIZUMAB; INTERLEUKIN 2 RECEPTOR ANTIBODY; METHYLPREDNISOLONE; METHYLPREDNISOLONE ACETATE; MYCOPHENOLIC ACID 2 MORPHOLINOETHYL ESTER; PREDNISONE; RAPAMYCIN; RECOMBINANT GRANULOCYTE COLONY STIMULATING FACTOR; STEROID; TACROLIMUS; THYMOCYTE ANTIBODY; VALGANCICLOVIR;

ARTICLE; BODY MASS; CHRONIC ALLOGRAFT NEPHROPATHY; CLINICAL PROTOCOL; CLINICAL TRIAL; CREATININE BLOOD LEVEL; CYTOMEGALOVIRUS INFECTION; DIABETES MELLITUS; DIARRHEA; DRUG EFFICACY; DRUG USE; DRUG WITHDRAWAL; EPSTEIN BARR VIRUS INFECTION; FOLLOW UP; GLOMERULUS FILTRATION RATE; GRAFT FAILURE; GRAFT RECIPIENT; GRAFT SURVIVAL; HUMAN; HYPERTRIGLYCERIDEMIA; IMMUNOSUPPRESSIVE TREATMENT; KIDNEY GRAFT REJECTION; KIDNEY TRANSPLANTATION; LEUKOPENIA; LOADING DRUG DOSE; LOW DRUG DOSE; LYMPHOPROLIFERATIVE DISEASE; NONHUMAN; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); STEROID THERAPY; TREATMENT DURATION; TREATMENT OUTCOME; VIRUS REPLICATION;

CLINICAL TRIALS AS TOPIC; GLUCOCORTICOIDS; GRAFT REJECTION; HUMANS; IMMUNOSUPPRESSIVE AGENTS; KIDNEY TRANSPLANTATION; PREDNISONE; PROGNOSIS; SIROLIMUS;

EID: 79958706027     PISSN: 09020063     EISSN: 13990012     Source Type: Journal    
DOI: 10.1111/j.1399-0012.2010.01282.x     Document Type: Article

References (64)

1. Citterio F. Steroid side effects and their impact on transplantation outcome. Transplantation 2001: 72(Suppl 12): S75.
2. Veenstra DL, Best JH, Hornberger J et al. Incidence and long-term cost of steroid-related side effects after renal transplantation. Am J Kidney Dis 1999: 33: 829.
3. Schweizer RT, Rovelli M, Palmeri D et al. Noncompliance in organ transplant recipients. Transplantation 1990: 49: 374.
4. Nevins TE, Kruse L, Skeans MA et al. The natural history of azathioprine compliance after renal transplantation. Kidney Int 2001: 60: 1565.
5. Prasad GVR, Nash MM, McFarlane PA et al. Renal transplant recipient attitudes toward steroid use and steroid withdrawal. Clin Transplant 2003: 17: 135.
6. Hricik DE, O'Toole MA, Schulak JA et al. Steroid-free immunosuppression in cyclosporine-treated renal transplant recipients: a meta-analysis. J Am Soc Nephrol 1993: 4: 1300.
7. Kasiske BL, Chakkera HA, Louis TA et al. A meta-analysis of immunosuppression withdrawal trials in renal transplantation. J Am Soc Nephrol 2000: 11: 1910.
8. Pascual J, Quereda C, Zamora J et al. Steroid withdrawal in renal transplant patients on triple therapy with a calcineurin inhibitor and mycophenolate mofetil: a meta-analysis of randomized, controlled trials. Transplantation 2004: 78: 1548.
9. Pascual J, Quereda C, Zamora J et al. Updated metaanalysis of steroid withdrawal in renal transplant patients on calcineurin inhibitor and mycophenolate mofetil. Transplant Proc 2005: 37: 3746.
10. ®, mycophenolate mofetil and a 6-month course of steroids. Am J Transplant 2007: 7: 2522.
11. Mahalati K, Kahan BD. A pilot study of steroid withdrawal from kidney transplant recipients on sirolimus-cyclosporine a combination therapy. Transplant Proc 2001: 33: 3232.
12. Citterio F, Sparacino V, Altieri P et al. Addition of sirolimus to cyclosporine in long-term kidney transplant recipients to withdraw steroid. Transplant Proc 2005: 37: 827.
13. Hricik DE, Knauss TC, Bodziak KA et al. Withdrawal of steroid therapy in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2003: 76: 938.
14. Hricik DE, Augustine JJ, Knauss TC et al. Long-term graft outcomes after steroid withdrawal in African American kidney transplant recipients receiving sirolimus and tacrolimus. Transplantation 2007: 83: 277.
15. Anil Kumar MS, Heifets M, Moritz MJ et al. Safety and efficacy of steroid withdrawal two days after kidney transplantation: analysis of results at three years. Transplantation 2006: 81: 832.
16. Anil Kumar MS, Heifets M, Fyfe B et al. Comparison of steroid avoidance in tacrolimus/mycophenolate mofetil and tacrolimus/sirolimus combination in kidney transplantation monitored by surveillance biopsy. Transplantation 2005: 80: 807.
17. Matas AJ, Kandaswamy R, Gillingham KY et al. Prednisone-free maintenance immunosuppression: a 5-year experience. Am J Transplant 2005: 5: 2473.
18. Gallon L, Perico N, Dimitrov BD et al. Long-term renal allograft function on a tacrolimus-based, pred-free maintenance immunosuppression comparing sirolimus vs MMF. Am J Transplant 2006: 6: 1617.
19. Gelens MA, Christiaans MH, Van Heurn EL et al. High rejection rate during calcineurin inhibitor-free and early steroid withdrawal immunosuppression in renal transplantation. Transplantation 2006: 82: 1221.
20. Jaber JJ, Feustel PJ, Elbahloul O et al. Early steroid withdrawal therapy in renal transplant recipients: a steroid-free sirolimus and CellCept-based calcineurin inhibitor-minimization protocol. Clin Transplant 2007: 21: 101.
21. Woodle ES, Vincenti F, Lorber MI et al. A multicenter pilot study of early (4-day) steroid cessation in renal transplant recipients under Simulect, tacrolimus and sirolimus. Am J Transplant 2005: 5: 157.
22. Rajab A, Pelletier RP, Henry ML et al. Long term outcome of steroid free maintenance immunosuppression with sirolimus and low dose cyclosporine in primary kidney transplantation. Am J Transplant 2008: 8(Suppl 2): 587.
23. Kandaswamy R, Melancon JK, Dunn T et al. A prospective randomized trial of steroid-free maintenance regimens in kidney transplant recipients-an interim analysis. Am J Transplant 2005: 5: 1529.
24. Kandaswamy R, Humar A, Dunn T et al. Prospective randomized trial of maintenance immunosuppression (IS) in prednisone (P)-free recipients: 5-year results. Am J Transplant 2008: 8(Suppl 2): 254.
25. Gallon LG, Winoto J, Chhabra D et al. Long-term renal transplant function in recipient of simultaneous kidney and pancreas transplant maintained with two prednisone-free maintenance immunosuppressive combinations: tacrolimus/mycophenolate mofetil versus tacrolimus/sirolimus. Transplantation 2007: 83: 1324.
26. Gelens MACJ, Christiaans MHC, Peutz-Kootstra CJ et al. Tacrolimus with fixed low dose sirolimus as good as tacrolimus with mycophenolate mofetil in renal transplantation with limited steroid exposure. Am J Transplant 2007: 7(Suppl 2): 450.
27. Rajab A, Pelletier RP, Henry ML et al. Excellent clinical outcomes in primary kidney transplant recipients treated with steroid-free maintenance immunosuppression. Clin Transplant 2006: 20: 537.
28. Ahsan N, Hricik D, Matas A et al. Prednisone withdrawal in kidney transplant recipients on cyclosporine and mycophenolate mofetil-a prospective randomized study. Transplantation 1999: 68: 1865.
29. Boardman RE, Alloway RR, Alexander JW et al. African-American renal transplant recipients benefit from early corticosteroid withdrawal under modern immunosuppression. Am J Transplant 2005: 5: 356.
30. Anil Kumar MS, Moritz MJ, Saaed MI et al. Avoidance of chronic steroid therapy in African American kidney transplant recipients monitored by surveillance biopsy: 1-year results. Am J Transplant 2005: 5: 1976.
31. Anil Kumar MS, Khan S, Ranganna K et al. Long-term outcome of early steroid withdrawal after kidney transplantation in African American recipients monitored by surveillance biopsy. Am J Transplant 2008: 8: 574.
32. Haririan A, Sillix DH, Morawski K et al. Short-term experience with early steroid withdrawal in African-American renal transplant recipients. Am J Transplant 2006: 6: 2396.
33. Sarwal MM, Cecka JM, Millan MT et al. Adult-size kidneys without acute tubular necrosis provide exceedingly superior long-term graft outcomes for infants and small children: a single center and UNOS analysis. Transplantation 2000: 70: 1728.
34. Fan X, Ang A, Pollock-Barziv SM et al. Donor-specific B-cell tolerance after ABO-incompatible infant heart transplantation. Nat Med 2004: 10: 1227.
35. Ueda M, Oike F, Ogura Y et al. Long-term outcomes of 600 living donor liver transplants for pediatric patients at a single center. Liver Transpl 2006: 12: 1326.
36. Harmon W, Alexander SR, Benfield M, et al. North American Pediatric Renal Transplant Cooperative Study (NAPRTCS): 2004 Annual Report. Renal transplantation, dialysis, chronic renal insufficiency. (accessed on March 17, 2008).
37. Harmon W, Fine R, Alexander S, et al. North American Pediatric Renal Trials and Collaborative Studies (NAPRTCS): 2007 Annual Report. Renal transplantation, dialysis, chronic renal insufficiency. (accessed on March 17, 2008).
38. Jabs K, Sullivan EK, Avner ED et al. Alternate-day steroid dosing improves growth without adversely affecting graft survival or long-term graft function. A report of the North American Pediatric Renal Transplant Cooperative Study. Transplantation 1996: 61: 31.
39. Chakrabarti P, Wong HY, Scantlebury VP et al. Outcome after steroid withdrawal in pediatric renal transplant patients receiving tacrolimus-based immunosuppression. Transplantation 2000: 70: 760.
40. Roberti I, Reisman L, Lieberman KV et al. Risk of steroid withdrawal in pediatric renal allograft recipients (a 5-year follow-up). Clin Transplant 1994: 8: 405.
41. Birkeland SA, Larsen KE, Rohr N. Pediatric renal transplantation without steroids. Pediatr Nephrol 1998: 12: 87.
42. Sarwal MM, Vidhun JR, Alexander SR et al. Continued superior outcomes with modification and lengthened follow-up of a steroid-avoidance pilot with extended daclizumab induction in pediatric renal transplantation. Transplantation 2003: 76: 1331.
43. Sarwal MM, Yorgin PD, Alexander S et al. Promising early outcomes with a novel, complete steroid avoidance immunosuppression protocol in pediatric renal transplantation. Transplantation 2001: 72: 13.
44. Sarwal M, Benfield M, Ettenger R et al. One year results of a prospective, randomized, multicenter trial of steroid avoidance in pediatric renal transplantation. Am J Transplant 2008: 8(Suppl 2): 192.
45. Li L, Chaudhuri A, Weintraub LA et al. Subclinical cytomegalovirus and Epstein-Barr virus viremia are associated with adverse outcomes in pediatric renal transplantation. Pediatr Transplant 2007: 11: 187.
46. Satterwhite T, Chua M-S, Hsieh S-C et al. Increased expression of cytotoxic effector molecules: different interpretations for steroid-based and steroid-free immunosuppression. Pediatr Transplant 2003: 7: 53.
47. Kim JS, Aviles DH, Silverstein DM et al. Effect of age, ethnicity, and glucocorticoid use on tacrolimus pharmacokinetics in pediatric renal transplant patients. Pediatr Transplant 2005: 9: 162.
48. Gallon LG, Winoto J, Leventhal JR et al. Effect of prednisone versus no prednisone as part of maintenance immunosuppression on long-term renal transplant function. Clin J Am Soc Nephrol 2006: 1: 1029.
49. Matas AJ, Kandaswamy R, Humar A et al. Long-term immunosuppression, without maintenance prednisone, after kidney transplantation. Ann Surg 2004: 240: 510.
50. Humar A, Kandaswamy R, Payne W et al. 6years of prednisone (P)-free maintenance immunosuppression (IS). Am J Transplant 2006: 6(Suppl 2): S482.
51. Woodle ES. Astellas Steroid Withdrawal Study Group. A randomized, double-blind, placebo-controlled trial of early corticosteroid cessation versus chronic corticosteroids: three year results. Am J Transplant 2006: 6(Suppl 2): S177.
52. Woodle ES. Astellas Steroid Withdrawal Group. A randomized double blind, placebo-controlled trial of early corticosteroid cessation versus chronic corticosteroids: five year results. Am J Transplant 2008: 8(Suppl 2): 300.
53. Ojo AO, Held PJ, Port FK et al. Chronic renal failure after transplantation of a nonrenal organ. N Engl J Med 2003: 349: 931.
54. Pelletier RP, Soule J, Henry ML et al. Clinical outcomes of renal transplant recipients treated with enteric-coated mycophenolic acid vs. mycophenolate mofetil as a switch agent using a primary steroid-free rapamune and microemulsion cyclosporine protocol. Clin Transplant 2007: 21: 532.
55. Donati D, Ambrosini A. Pilot study of thymoglobulin (THY) followed by sirolimus (SRL) as maintenance monotherapy. A calcineurin inhibitor (CNI) free, steroid sparing and likely tolerogenic protocol for kidney transplantation (ktx): 5year follow up. Am J Transplant 2007: 7(Suppl 2): 160.
56. Flechner SM, Friend P, Bockman J et al. Campath 1H induction and sirolimus plus mycophenolate mofetil maintenance for CNI and steroid-free kidney transplant immunosuppression. Am J Transplant 2005: 5(Suppl 11): 541.
57. Rajab A, Pelletier RP, Henry ML et al. A prospective study of steroid free, calcineurin inhibitor free maintenance immunosuppression based on Rapamune/Myfortic in kidney transplantation. Am J Transplant 2008: 8(Suppl 2): 585.
58. Knechtle SJ, Pirsch JD, Fechner H et al. Campath-1H induction plus rapamycin monotherapy for renal transplantation: results of a pilot study. Am J Transplant 2003: 3: 722.
59. Alexander JW, Goodman HR, Cardi M et al. Simultaneous corticosteroid avoidance and calcineurin inhibitor minimization in renal transplantation. Transpl Int 2006: 19: 295.
60. Maes BD, Lemahieu W, Kuypers D et al. Differential effect of diarrhea on FK506 versus cyclosporine A trough levels and resultant prevention of allograft rejection in renal transplant recipients. Am J Transplant 2002: 2: 989.
61. Molinari M, Al-Saif F, Ryan EA et al. Sirolimus-induced ulceration of the small bowel in islet transplant recipients: report of two cases. Am J Transplant 2005: 5: 2799.
62. Taber DJ, Ashcraft E, Baillie GM et al. Valganciclovir prophylaxis in patients at high risk for the development of cytomegalovirus disease. Transpl Infect Dis 2004: 6: 101.
63. Ciancio G, Burke GW, Mattiazzi A et al. Cytomegalovirus prophylaxis with valganciclovir in kidney, pancreas-kidney, and pancreas transplantation. Clin Transplant 2004: 18: 402.
64. Laftavi MR, Stephan R, Stefanick B et al. Randomized prospective trial of early steroid withdrawal compared with low-dose steroids in renal transplant recipients using serial protocol biopsies to assess efficacy and safety. Surgery 2005: 137: 364.